GlassScriptPhysician profile
Bruce A Daniels
NPI 1972584050
$736.39
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $89.27.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.02 | 2019-2020 | |
| Allergan, INC. | $118.32 | 2019-2020 | |
| Pfizer INC. | $93.58 | 2019 | |
| Lilly USA, LLC | $50.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.58 | 2019-2020 | |
| Medtronic Minimed, INC. | $15.84 | 2019 | |
| Amgen INC. | $14.77 | 2019 | |
| Amarin Pharma, INC. | $11.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.